Oncotelic Therapeutics, Inc.

Equities

OTLC

US6283411097

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:55:43 2024-04-26 pm EDT			5-day change	1st Jan Change
0.042 ^USD	+2.94%		+6.60%	+9.66%

Apr. 12	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 25	Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	CI

Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 22, 2023 at 06:12 am EDT

Oncotelic Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 0.525419 million compared to USD 4.85 million a year ago.

Latest news about Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	Mar. 25	CI
Earnings Flash (OTLC) ONCOTELIC THERAPEUTICS Posts Q3 Revenue $70,000	Nov. 15	MT
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Oncotelic Therapeutics, Inc. announces tranche update	23-10-23	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Oncotelic Launches PDAO SEC chatbot	23-04-24	CI
Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology	23-04-19	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Oncotelic Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-04-13	CI
Oncotelic Therapeutics, Inc Announces The Publication of High Intra-Tumor Transforming Growth Factor ?2 Level as A Predictor of Poor Treatment Outcomes in Pediatric Cancer of the Brainstem	23-03-13	CI
Oncotelic Therapeutics, Inc. announced that it expects to receive $5 million in funding	23-03-09	CI
Oncotelic Therapeutics, Inc. Announces Executive Changes	23-03-02	CI
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer	23-02-06	CI
Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer	23-01-25	CI
Oncotelic Therapeutics, Inc. Announces Launch of Wholly Owned Subsidiary, Pet2DAO Inc. and its Associated Token PDAO	23-01-17	CI
Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022	22-12-19	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
Oncotelic Initiates Clinical Trials Evaluating OT-101 Against Pediatric Gliomas	22-11-08	CI
Oncotelic Therapeutics, Inc. cancelled the transaction announced on October 25, 2021	22-10-24	CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22	CI
Oncotelic Therapeutics, Inc. announced that it has received $0.3015 million in funding from BlueLake Partners, LLC	22-06-21	CI
Oncotelic Therapeutics, Inc. announced that it has received $0.5445 million in funding from Mast Hill Management, LLC	22-05-26	CI
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma	22-05-25	CI

Chart Oncotelic Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Companyâs pipeline includes OT-101, CA4P and Oxi4503. OT-101 is antisense against TGF-2 for the treatment of solid tumors with focus on brain cancer in adults and diffuse intrinsic pontine glioma (DIPG) in children. OT-101 is antisense against TGF-2 for the treatment of various viruses, including the SARS and the COVID-19, on its own and in conjunction with other compounds. CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. Oxi4503 is VDA for the treatment of liquid tumors with a focus on childhood leukemia.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ONCOTELIC THERAPEUTICS, INC.	+9.66%	16.79M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs